New Diabetes Drug by University of Utah

Released on = March 28, 2007, 2:25 am

Press Release Author = Shushmul Maheshwari

Industry = Healthcare

Press Release Summary = A new study by University of Utah may proffer an innovative
drug for the treatment of diabetes, a chronic disease with over 20 million Americans
as its patients.

Press Release Body = The study by University of Utah was conducted on mice and rats
that develop diseases similar to diabetes. The study showed that obstructing the
formation of a fat molecule, called ceramide, helped check insulin resistance.
Ceramide is connected to saturated fats, stated Scott Summers, Ph.D., Associate
Professor of internal medicine and one of the authors of the study, in a statement
reported on March 7, 2007 by The Salt Lake Tribune.

The findings may give new ways of treating or even preventing the type 2 diabetes.
Also, to an extent, it has the potential to treat type 1 diabetes also, something
researchers have a grant to look into, said Summers.

He added, "If we pre-treated with this drug, [the animals] never became diabetic".
This kind of treatment would be for people suffering from type 2 diabetes, the most
common diabetes form, said Summers.

According William Holland, the lead author of the study, on March 7, 2007, said in a
statement reported by The Salt Lake Tribune, that some existing drug treatments make
the body more susceptible to the quantum of the insulin produced naturally in the
body. But the findings of the University of Utah proffer another way to treat the
insulin resistance.

"We show that preventing ceramide accumulation in a number of different [mouse and
rat] models . . . will improve insulin sensitivity", added Holland.

The drugs tested on animal models may cause severe side effects in human beings. So
pharmaceutical firms will have to look for new methods to target ceramide molecule
in patients. It could take a long time of 10 years before a suitable human drug
passes through the stage of clinical trials.

The RNCOS report "New Developments in Insulin Delivery System (2006)" projects the
diabetes drugs and equipment market to go beyond US$ 20 Billion by 2010. This
segment continues to see radical development in research for both technologies and
therapeutic compounds in drug delivery.

The market research report provides an insight into the global diabetes drug market.
It highlights the worldwide trends in insulin supply and demand, insulin delivery
market, various diabetes treatments (including gene therapy, pump therapy, and
Xenotransplantation), key drivers, and future outlook of the market.

About RNCOS:

RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of
industry experts who analyze data collected from credible sources. They provide
industry insights and analysis that helps corporations to take timely and accurate
business decision in today\'s globally competitive environment.

For more information visit: http://www.rncos.com/Report/IM040.htm
Current Industry News: http://www.rncos.com/blog


Web Site = http://www.rncos.com

Contact Details = RNCOS E-Services Pvt Ltd.
Shushmul Maheshwari
Head of Business Development
29, 1st Floor, Patparganj Industrial Area, Delhi 92
91-11-4214-1229
info@rncos.com

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •